Take up the challenge for your eligible patients – who are the patients?
Seminar
•
AstraZeneca
About the CPD course
The presentation aims to highlight eligible patients for LYNPARZA (olaparib) combination therapy in mCRPC. The presentation will discuss a hypothetical eligible patient for LYNPARZA and will explore how his treatment can be managed to achieve prolonged median rPFS; as well as management of adverse events and dosing.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines.
Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive, open and collaborative. This approach runs through all that we do.
